CrystalGenomics, Inc. (083790.KQ)
KRW 2545.0
(0.99%)
KRW 2545.0
(0.99%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -48.92 Billion KRW | -104.97% |
| 2022 | -23.86 Billion KRW | -50.11% |
| 2021 | -15.9 Billion KRW | -61.63% |
| 2020 | -9.83 Billion KRW | -708.33% |
| 2019 | -37.58 Billion KRW | 20.91% |
| 2018 | 6.9 Billion KRW | 4.42% |
| 2017 | -8.57 Billion KRW | 3.21% |
| 2016 | -2.17 Billion KRW | 6.96% |
| 2015 | -4.84 Billion KRW | 8.46% |
| 2014 | -11.93 Billion KRW | 5.24% |
| 2013 | -11.4 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -14.25 Billion KRW | -89.72% |
| 2024 Q1 | -7.51 Billion KRW | 76.07% |
| 2023 FY | -48.92 Billion USD | -104.97% |
| 2023 Q1 | -4.47 Billion USD | -1038.91% |
| 2023 Q3 | 20.9 Billion USD | 161.55% |
| 2023 Q2 | -33.96 Billion KRW | -659.09% |
| 2023 Q4 | -31.38 Billion USD | -250.16% |
| 2022 FY | -23.86 Billion USD | -50.11% |
| 2022 Q3 | 810.04 Million USD | 0.0% |
| 2022 Q1 | 592.57 Million USD | 25.61% |
| 2022 Q4 | 476.54 Million USD | -41.17% |
| 2021 Q4 | 471.75 Million USD | -39.96% |
| 2021 FY | -15.9 Billion USD | -61.63% |
| 2021 Q1 | 596.16 Million USD | 34.75% |
| 2021 Q3 | 785.77 Million USD | 0.0% |
| 2020 Q1 | 342.89 Million USD | -2.12% |
| 2020 Q3 | 740.45 Million USD | 0.0% |
| 2020 Q4 | 442.43 Million USD | -40.25% |
| 2020 FY | -9.83 Billion USD | -708.33% |
| 2019 Q1 | 405.94 Million USD | 37.78% |
| 2019 Q3 | 565.22 Million USD | 0.0% |
| 2019 FY | 1.61 Billion USD | 20.91% |
| 2019 Q4 | 350.33 Million USD | -38.02% |
| 2018 Q4 | 294.63 Million USD | -26.39% |
| 2018 FY | 1.33 Billion USD | 4.42% |
| 2018 Q3 | 400.28 Million USD | 0.0% |
| 2018 Q1 | 366.72 Million USD | 26.66% |
| 2017 FY | 1.28 Billion USD | 3.21% |
| 2017 Q1 | 331.7 Million USD | 39.87% |
| 2017 Q3 | 433.9 Million USD | 0.0% |
| 2017 Q4 | 289.53 Million USD | -33.27% |
| 2016 FY | 1.24 Billion USD | 6.96% |
| 2016 Q4 | 237.14 Million USD | -44.43% |
| 2016 Q3 | 426.76 Million USD | 0.0% |
| 2016 Q1 | 327.51 Million USD | 43.26% |
| 2015 Q3 | 401.13 Million USD | 0.0% |
| 2015 Q1 | 309.07 Million USD | 29.69% |
| 2015 FY | 1.16 Billion USD | 8.46% |
| 2015 Q4 | 228.61 Million USD | -43.01% |
| 2014 FY | 1.06 Billion USD | 5.24% |
| 2014 Q1 | 285.15 Million USD | 30.75% |
| 2014 Q3 | 373.67 Million USD | 0.0% |
| 2014 Q4 | 238.31 Million USD | -36.22% |
| 2013 Q1 | 265.58 Million USD | 50.69% |
| 2013 Q4 | 218.08 Million USD | -41.25% |
| 2013 FY | 1.01 Billion USD | 0.0% |
| 2013 Q3 | 371.19 Million USD | 0.0% |
| 2012 Q4 | 176.24 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Co., Ltd. | -189.07 Billion KRW | 74.125% |
| iNtRON Biotechnology, Inc. | -9.69 Billion KRW | -404.606% |
| BINEX Co., Ltd. | 4.67 Billion KRW | 1147.447% |
| Bioneer Corporation | -10.58 Billion KRW | -362.109% |
| Anterogen.Co.,Ltd. | -2.84 Billion KRW | -1622.148% |
| MEDIPOST Co., Ltd. | 5.83 Billion KRW | 937.734% |
| Helixmith Co., Ltd | -64.08 Billion KRW | 23.662% |
| Chabiotech Co.,Ltd. | -8.43 Billion KRW | -480.266% |
| Medy-Tox Inc. | 9.75 Billion KRW | 601.519% |
| Peptron, Inc. | -15.92 Billion KRW | -207.273% |
| Amicogen, Inc. | -23.28 Billion KRW | -110.073% |
| Genexine, Inc. | -66.87 Billion KRW | 26.842% |
| HLB Therapeutics Co.,Ltd. | -2.3 Billion KRW | -2025.12% |
| LegoChem Biosciences, Inc. | -73.7 Billion KRW | 33.621% |
| ALTEOGEN Inc. | -3.37 Billion KRW | -1350.98% |
| PharmaResearch Co., Ltd. | 76.55 Billion KRW | 163.91% |
| SillaJen, Inc. | -20.36 Billion KRW | -140.184% |
| JETEMA, Co., Ltd. | 13.96 Billion KRW | 450.307% |
| OliX Pharmaceuticals,Inc | -19.1 Billion KRW | -156.122% |
| Genomictree Inc. | -8.75 Billion KRW | -458.742% |
| MedPacto, Inc. | -35.32 Billion KRW | -38.497% |
| D&D Pharmatech | 3.93 Billion KRW | 1343.672% |
| EASY BIO,Inc. | 15.54 Billion KRW | 414.747% |
| GI Innovation, Inc. | -55.49 Billion KRW | 11.842% |